Maze Therapeutics Inc. has described sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors reported to be useful for the treatment of phenylketonuria, metabolic syndrome, chronic kidney disease and metabolic diseases.
Researchers at Biogen Inc. and Broad Institute Inc. have divulged glycogen synthase kinase-3α (GSK3A; GSK-3α) inhibitors reported to be useful for the treatment of cancer, neurological and metabolic diseases.
Norroy Bioscience Co. Ltd. has identified conjugates comprising fibroblast activation protein α (FAP)-targeting agents covalently linked to cytotoxic drugs or unlabeled or radiolabeled imaging agents through a linker acting as FAP ligands reported to be useful for diagnosis and treatment of cancer expressing FAP.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized 3C-like proteinase (3CLpro, Mpro) (coronavirus) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome infections.
Astrazeneca AB has disclosed CX3C chemokine receptor 1 (CX3CR1; CMKBRL1; GPR13) antagonists reported to be useful for the treatment of heart failure, among others.
Asieris Pharmaceuticals Co. Ltd. has described indole phthalocyanine compounds acting as fluorescence imaging agents with high contrast reported to be useful for the diagnosis of bladder cancer.
Sunshine Lake Pharma Co Ltd. has identified pyrimidopyridine compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
B&A Oncomedical SAS has synthesized solute carrier family 12 member 2 (SLC12A2; NKCC1) inhibitors reported to be useful for the treatment of cancer, schizophrenia, autistic spectrum disorders, fragile X syndrome, Rett syndrome, Down syndrome, Parkinson’s disease and temporal lobe epilepsy, among others.
Genesis Therapeutics Inc. has disclosed phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer.